Effects of combined traditional Chinese medicine with immunosuppressive agents for patients with myasthenia gravis
- PMID: 26770531
- PMCID: PMC4694431
Effects of combined traditional Chinese medicine with immunosuppressive agents for patients with myasthenia gravis
Abstract
Myasthenia gravis (MG) is a kind of autoimmune disease induced by transferring dysfunction of neuromuscular junction. In the present study, we developed an integrated therapy combined with traditional Chinese medicine and immuno suppressive agents to seek for an effective treatment of MG. 220 MG patients were randomly divided into two groups with different therapies. Plasma levels of acetylcholine receptors antibodies (AchRAb) and CD4(+)CD25(+) regulatory T cells (CD4(+)CD25(+)Treg) were conducted through ELISA and flow cytometry. The amount of AchRAb (8.52±0.96 vs. 5.22±0.46) and CD4(+)CD25(+)Treg (1.94±1.21 vs. 3.21±0.96) in Group A receiving integrated therapy were significantly improved compared with Group B; the clinical performance of group treated with the integrated therapy was also much better. The integrated therapy in the present study could significantly improve the condition of MG with high recovery rate and low recurrence rate, which can be employed in future clinical treatment of MG.
Keywords: Myasthenia gravis; clinical performance; immunosuppressor; integrated treatment; traditional Chinese medicine.
Figures
Similar articles
-
CD4+ CD25(high) regulatory T cell in childhood ocular myasthenia gravis.Brain Dev. 2011 May;33(5):442-4. doi: 10.1016/j.braindev.2010.08.002. Epub 2010 Aug 24. Brain Dev. 2011. PMID: 20797828
-
Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients.J Neuroimmunol. 2010 Aug 25;225(1-2):123-31. doi: 10.1016/j.jneuroim.2010.03.016. Epub 2010 May 15. J Neuroimmunol. 2010. PMID: 20472307
-
Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment.Immunology. 2005 Sep;116(1):134-41. doi: 10.1111/j.1365-2567.2005.02220.x. Immunology. 2005. PMID: 16108825 Free PMC article.
-
Myasthenia and the neuromuscular junction.Curr Opin Neurol. 2012 Oct;25(5):523-9. doi: 10.1097/WCO.0b013e3283572588. Curr Opin Neurol. 2012. PMID: 22892950 Review.
-
Clinical and scientific aspects of acetylcholine receptor myasthenia gravis.Curr Opin Neurol. 2014 Oct;27(5):552-7. doi: 10.1097/WCO.0000000000000125. Curr Opin Neurol. 2014. PMID: 25105461 Review.
Cited by
-
iTRAQ-Based Proteomics Analysis of Plasma of Myasthenia Gravis Patients Treated with Jia Wei Bu Zhong Yi Qi Decoction.Evid Based Complement Alternat Med. 2019 Dec 13;2019:9147072. doi: 10.1155/2019/9147072. eCollection 2019. Evid Based Complement Alternat Med. 2019. PMID: 31915455 Free PMC article.
-
Effectiveness of modified Buzhong Yiqi decoction in treating myasthenia gravis: study protocol for a series of N-of-1 trials.Trials. 2022 Apr 27;23(1):365. doi: 10.1186/s13063-022-06287-9. Trials. 2022. PMID: 35477531 Free PMC article.
-
Efficacy and Safety of the TCM Qi-Supplementing Therapy in Patients with Myasthenia Gravis: A Systematic Review and Meta-Analysis.Evid Based Complement Alternat Med. 2017;2017:6512572. doi: 10.1155/2017/6512572. Epub 2017 Dec 3. Evid Based Complement Alternat Med. 2017. PMID: 29333187 Free PMC article. Review.
References
-
- Lee SJ, Hur J, Lee TW, Ju S, Lee SH, Park KJ, Cho YJ, Jeong YY, Lee JD, Kim HC. Myasthenia gravis presenting initially as acute respiratory failure. Respir Care. 2015;60:e14–16. - PubMed
-
- Gilhus NE, Nacu A, Andersen JB, Owe JF. Myasthenia gravis and risks for comorbidity. Eur J Neurol. 2015;22:17–23. - PubMed
-
- Wang WW, Hao HJ, Gao F. Detection of multiple antibodies in myasthenia gravis and its clinical significance. Chin Med J (Engl) 2010;123:2555–2558. - PubMed
-
- Somnier FE, Keiding N, Paulson OB. Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey. Arch Neurol. 1991;48:733–739. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials